Partners Confirmed For 2020
We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC-induced protein degradation: compound binding and permeability, ternary complex formation, ubiquitination, and trafficking to proteasome. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.
LifeSensors generates reagents and drug discovery platforms which enable researchers to accurately and effectively assay the Ubiquitin Proteasome System. In addition to off-the-shelf products and kits, LifeSensors also partners with companies and researchers around the world to develop novel drug discovery assays. LifeSensors’ powerful technologies in conjunction with our expertise in the UPS, have enabled researchers to target and assay the undruggable targets.
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases. Our lead molecule targets Acute Myeloid Leukemia (in clinic Q2 2019) and our lead Protein Homeostatic Modulator (PHM™) will be in the clinic Q3 2020 for hematological malignancies.